China Clears IASO208 for Clinical Study

IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.

IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.

Recovered source-gap item: IASO Bio disclosed November 10 investigator-initiated data in three severe refractory lupus nephritis patients with nine months of follow-up. All achieved at least partial renal remission; two complete renal remission. These…

FDA cleared IASO208, a CD20-directed in vivo CAR-T candidate built on a replication-incompetent, self-inactivating third-generation lentiviral vector, for U.S. clinical testing in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. IASO Bio expects to…